China Resources Pharmaceutical Group Ltd - ESG Rating & Company Profile powered by AI
This ESG rating for China Resources Pharmaceutical Group Ltd represents the company's transparency towards the UN Sustainable Development Goals. This analysis of China Resources Pharmaceutical Group Ltd leverages intelligence from across the web and also from public filings by China Resources Pharmaceutical Group Ltd. Full Sustainability assessment of China Resources Pharmaceutical Group Ltd are accessed by registering for free.
China Resources Pharmaceutical Group Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.4; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.3.
0.4
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1924 | Sigma Healthcare Ltd | 0.5 | Low |
1924 | Uni-Bio Science Group Ltd | 0.5 | Low |
1952 | China Resources Pharmaceutical Group Ltd | 0.4 | Low |
1952 | CFR Pharmaceuticals SA | 0.4 | Low |
1952 | CellSource Co Ltd | 0.4 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does China Resources Pharmaceutical Group Ltd have an accelerator or VC vehicle to help deliver innovation?
Does China Resources Pharmaceutical Group Ltd disclose current and historical energy intensity?
Does China Resources Pharmaceutical Group Ltd report the average age of the workforce?
Does China Resources Pharmaceutical Group Ltd reference operational or capital allocation in relation to climate change?
Does China Resources Pharmaceutical Group Ltd disclose its ethnicity pay gap?
Does China Resources Pharmaceutical Group Ltd disclose cybersecurity risks?
Does China Resources Pharmaceutical Group Ltd offer flexible work?
Does China Resources Pharmaceutical Group Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does China Resources Pharmaceutical Group Ltd disclose the number of employees in R&D functions?
Does China Resources Pharmaceutical Group Ltd conduct supply chain audits?
Does China Resources Pharmaceutical Group Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does China Resources Pharmaceutical Group Ltd conduct 360 degree staff reviews?
Does China Resources Pharmaceutical Group Ltd disclose the individual responsible for D&I?
Does China Resources Pharmaceutical Group Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does China Resources Pharmaceutical Group Ltd disclose current and / or historical scope 2 emissions?
Does China Resources Pharmaceutical Group Ltd disclose water use targets?
Does China Resources Pharmaceutical Group Ltd have careers partnerships with academic institutions?
Did China Resources Pharmaceutical Group Ltd have a product recall in the last two years?
Does China Resources Pharmaceutical Group Ltd disclose incidents of discrimination?
Does China Resources Pharmaceutical Group Ltd allow for Work Councils/Collective Agreements to be formed?
Has China Resources Pharmaceutical Group Ltd issued a profit warning in the past 24 months?
Does China Resources Pharmaceutical Group Ltd disclose parental leave metrics?
Does China Resources Pharmaceutical Group Ltd disclose climate scenario or pathway analysis?
Does China Resources Pharmaceutical Group Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does China Resources Pharmaceutical Group Ltd disclose the pay ratio of women to men?
Does China Resources Pharmaceutical Group Ltd support suppliers with sustainability related research and development?
Does China Resources Pharmaceutical Group Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does China Resources Pharmaceutical Group Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is China Resources Pharmaceutical Group Ltd involved in embryonic stem cell research?
Does China Resources Pharmaceutical Group Ltd disclose GHG and Air Emissions intensity?
Does China Resources Pharmaceutical Group Ltd disclose its waste policy?
Does China Resources Pharmaceutical Group Ltd report according to TCFD requirements?
Does China Resources Pharmaceutical Group Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does China Resources Pharmaceutical Group Ltd disclose energy use targets?
Does China Resources Pharmaceutical Group Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does China Resources Pharmaceutical Group Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for China Resources Pharmaceutical Group Ltd
These potential risks are based on the size, segment and geographies of the company.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.